>
>
>
Monoclonal antibodies (mAbs) are central to ADCs and diagnostics. Our facility develops high-specificity antibodies that serve dual purposes:
Diagnostic Biomarkers for early-stage cancer detection
Therapeutic Agents for ADC-based treatments
Targeting overexpressed cancer proteins in both early and late stages enables highly sensitive detection and inhibition of tumor progression.
Genomic & Proteomic Profiling via MALDI-Mass Spectroscopy
To support precision oncology, we offer genomic and proteomic profiling using MALDI-MS for:
Early Cancer Biomarker Discovery
Therapeutic Target Identification
Treatment Response Prediction
We analyze
DNA methylation patterns
MicroRNAs (miRNAs)
Antitumor antibodies
Plasma protein profiles
EGFR, ALK, ROS1, HER2, BRCA, and more
This integrated profiling empowers clinicians and researchers with deep biological insights and personalized treatment plans.
